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A B S T R A C T   
Loxoscelism is one of the most important forms of araneism in South America. The Health Authorities from 
countries with the highest incidence and longer history in registering loxoscelism cases indicate that specific 
antivenom should be administered during the first hours after the accident, especially in the presence or at risk of 
the most severe clinical outcome. Current antivenoms are based on immunoglobulins or their fragments, ob-
tained from plasma of hyperimmunized horses. Antivenom has been produced using the same traditional 
techniques for more than 120 years. Although the whole composition of the spider venom remains unknown, the 
discovery and biotechnological production of the phospholipase D enzymes represented a milestone for the 
knowledge of the physiopathology of envenomation and for the introduction of new innovative tools in anti-
venom production. The fact that this protein is a principal toxin of the venom opens the possibility of replacing 
the use of whole venom as an immunogen, an attractive alternative considering the laborious techniques and low 
yields associated with venom extraction. This challenge warrants technological innovation to facilitate pro-
duction and obtain more effective antidotes. In this review, we compile the reported studies, examining the 
advances in the expression and application of phospholipase D as a new immunogen and how the new 
biotechnological tools have introduced some degree of innovation in this field.   
1. Introduction: Loxosceles genus and loxoscelism 
The genus Loxosceles belongs to the spider family Sicariidae, which 
comprises three genera: Hexophthalma, with 6 species from Africa; 
Sicarius, with 21 species distributed in Central and South America; and 
Loxosceles, with 139 described species worldwide (Magalh~aes et al., 
2017; World Spider Catalog, 2020). While most species of the genus 
Loxosceles have been described in Central America, South America and 
Africa, some in North America, the number of species recorded in 
Europe and Asia is still very limited (World Spider Catalog, 2020). 
All Loxosceles species, commonly named “violin” spiders, are light to 
dark brown, uniformly colored, and have six sets of eyes displayed in a 
characteristic pattern of three pairs, and relatively long, slim legs 
(Magalh~aes et al., 2017; Vetter, 2008). They share a distinct mark that 
resembles a violin in the dorsal side of the cephalothorax, which is dark 
brown on light brown carapace (Fig. 1a and b). Traditionally, different 
groups of species have been recognized based on the morphological 
characters: in North America (L. reclusa) (Gertsch and Ennik, 1983), in 
South America (L. gaucho, L. laeta, L. amazonica, L. spadicea, L. inter-
media) (Gertsch, 1967), in South Africa (L. vonwredei, L. spinulosa) 
(Newlands and Atkinson, 1988), and in the Mediterranean (L. rufescens) 
(Nentwig et al., 2017). The species group amazonica has been recently 
synonymized with the species group rufescens (Duncan et al., 2010; 
Fukushima et al., 2017; Valdez-Mondrag�on et al., 2019). 
Accidents caused by these spiders, known as loxoscelism, are often 
intra or peridomiciliary and constitute a public health problem. Despite 
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the widespread distribution of the species, clinical cases of Loxosceles 
spider bites are more commonly reported in the Americas, especially in 
Brazil, where the number of accidents has increased in the past few years 
(Ribeiro de Oliveira Mendes et al., 2020). In 2017, the Brazilian Ministry 
of Health computed 7992 cases of loxoscelism, nine of which resulted in 
deaths, and in Southern Brazil, the state of Paran�a alone concentrated 
4085 reports of brown spider bites and one death in the same year 
(Ribeiro de Oliveira Mendes et al., 2020). In Argentina, Brazil and Peru, 
countries that taken together represent the vast majority of reported 
loxoscelism cases around the world, the use of the specific antivenom to 
treat loxoscelism is recommended by their Ministries of Health (Instituto 
Nacional de Salud, 2004; Minist�erio da Saúde, 2001; Ministerio de 
Salud, 2012). In Europe, scarse cases have been reported, mostly 
showing only local manifestations (Atilla et al., 2004; Bajin et al., 2011; 
Farace et al., 2006; Jerusalem and Salavert Lletí, 2018; Morales-Moreno 
et al., 2016; Ribuffo et al., 2012; Rubenstein et al., 2016). The venoms of 
Loxosceles spiders from the Old and New Worlds are likely to produce 
comparable clinical pictures (Planas et al., 2015). 
Loxoscelism is a toxic condition caused by the venom inoculated by 
the bite of the spider. The initial bite frequently occurs without imme-
diate pain, and evident signs or symptoms are absent in the first few 
hours; thus, the clinical consultation with a specialist is frequently 
delayed for at least 24 h since the accident. As a consequence, the precise 
diagnosis of loxoscelism is difficult and usually presumptive, and the 
symptomatology is sometimes confused with bacterial or viral cuta-
neous infections, dermatitis, vasculitis, or diabetic ulcer (Vetter and 
Isbister, 2008). Most accidents caused by Loxosceles spider envenom-
ation are characterized by dermonecrotic lesions with gravitational 
spreading, and hence, these accidents are often referred to as necrotic or 
gangrenous arachnidism. However, in over 10% of the cases, particu-
larly when L. laeta is responsible for the accident, systemic evolution of 
the pathology is observed, which can result in a fatal outcome, mostly in 
children and elders. Venom toxins are responsible for many cellular 
changes that follow envenomation, either in humans or in animal 
models for experimental exposure. When rabbit skin is exposed to 
venom, it shows the same injuries seen in human biopsies: a dermo-
necrosis with massive infiltration of inflammatory cells into the dermis 
(Barbaro et al., 1992; Ospedal et al., 2002). 
Less frequently, systemic manifestations take place, including renal 
alterations and hematological disturbances such as hemolysis, throm-
bocytopenia, and intravascular coagulation (Da Silva et al., 2004). There 
is no consensus on cutaneous loxoscelism treatment, several alternatives 
are mentioned in the literature and usually include analgesics, anti-
venoms, corticoids, dapsone and, eventually, antibiotics (Hogan et al., 
2004; Instituto Nacional de Salud, 2004; Minist�erio da Saúde, 2001; 
Ministerio de Salud, 2012). Recent reports show a beneficial effect of 
tetracycline treatment on experimental models of both cutaneous and 
systemic loxoscelism, which suggests a potential implementation of this 
therapeutic agent in the not-too-distant future (Okamoto et al., 2017; 
Paix~ao-Cavalcante et al., 2007). Nevertheless, the experience gained 
after several decades of loxoscelism treatment in most of the countries 
with the highest incidence and longest historical records of loxoscelism 
shows consensus on their Health Authorities to indicate antivenom 
administration to patients with evident of cutaneous lesions, and it is the 
only available therapeutic tool today for treating systemic loxoscelism. 
Antivenom has been obtained by immunizing horses with spider 
venoms since the early 1960s, and it has great efficiency if administered 
soon after the bite. Unfortunately, venom extraction for antivenom 
production from the spiders is a very laborious task with very low yields 
per spider. Therefore, the search for alternatives to complement or 
substitute the use of venom during antivenom production by recombi-
nant alternatives has been the focus of many work during the last two 
decades. 
1.1. Venom toxins 
The genus Loxosceles has been extensively studied in the fields of 
pharmacology, biochemistry, immunology, and biotechnology, and 
some of the venom components have been well biochemically and bio-
logically characterized (Chatzaki et al., 2012; Dantas et al., 2014; 
Kalapothakis et al., 2002; Silvestre et al., 2005). In nature, brown spiders 
are arthropods that use their venom for predation and defense. Less than 
2 μL of a highly viscous, clear liquid containing about 50 μg of proteins 
can usually be extracted from the venom gland of an adult specimen. 
Nevertheless, Loxosceles spider venom is quite complex and can be 
classified as highly expressed (phospholipases, metalloproteases, and 
inhibitor cystine knot family peptides) and lowly expressed (serine 
proteases, protease inhibitors, hyaluronidases, allergen/like toxins, and 
histamine-releasing effectors) polypeptides. The toxicity profiles of 
Loxosceles venoms are similar between female and male specimens and 
between distinct species, such as L. laeta, L. reclusa, L. intermedia, L. 
adelaida, L. similis, and L.gaucho (Chaves-Moreira et al., 2017). Frac-
tionation by gel filtration of whole venom suggested that most, if not all, 
relevant in vivo toxicity from brown spider venom comes from compo-
nents with a molecular weight of about 35 kDa. This observation was 
later confirmed by recombinant expression and in vivo testing of various 
isoforms from the phospholipase D (PLD) present in this fraction. Thus, 
the protein family of PLD enzymes, the most abundantly expressed 
Fig. 1. a: Loxosceles laeta male. b: Loxosceles laeta female.  
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proteins in Loxosceles venoms, are mostly responsible for the local and 
systemic effects of loxoscelism (Kalapothakis et al., 2007; Veiga et al., 
2000). 
Other abundant components of Loxosceles venom are a group of 
20–30 kDa astacin-like metalloproteases, and a series of 5.6–7.9 kDa 
peptide members of the inhibitor cystine knot family (ICK) (De Castro 
et al., 2004; Matsubara et al., 2017, 2013). The first description of 
peptides from the ICK in Loxosceles venoms was reported in 2004 (De 
Castro et al., 2004). The authors isolated a group of small peptides from 
the venom of L. intermedia with insecticidal activities against Spodoptera 
frugiperda and Spodoptera cosmioides and named them LiTx1, LiTx2, and 
LiTx3. These peptides have molecular masses ranging from 5.6 to 7.9 
kDa, and further analysis of the sequences suggested the presence of 
possible post-translational modification regions in the sequences of 
LiTx1-3, such as N-myristoylation, amidation, and casein kinase II 
phosphorylation sites and their activity against ion channels. 
The less abundant components of this venom include other pro-
teases, from the serine proteases family (between 85 and 95 kDa mo-
lecular weight) (Veiga et al., 2000) and also protease inhibitors named 
serpins (Fernandes-Pedrosa et al., 2008; Gremski et al., 2010). Members 
of the Translationally Controlled Tumor Proteins (TCTP) family have 
also been detected in this venom (Gremski et al., 2010). These proteins 
act as histamine-releasing effectors, proposed to be related to erythema, 
diffusion of the venom, itching, pain, and less frequently, cases of hy-
persensitivity or even allergic reactions after venom inoculation 
(Boia-Ferreira et al., 2019; Sade et al., 2012). At least three hyaluroni-
dase isoforms of 41–43 kDa have been detected in Loxosceles venom, 
some of them also recombinant expressed (da Silveira et al., 2007; 
Fernandes-Pedrosa et al., 2008; Gremski et al., 2010). Studies in rabbit 
skin with recombinant hyaluronidase showed induction of local toxicity 
when co-administered with recombinant dermonecrotic toxin (Ferrer 
et al., 2013). Finally, other minor components from Loxosceles venom 
also include hydrolases, lipases, c-type lectins peptidases, collagenases, 
alkaline phosphatases, 5-ribonucleotidases, and phosphohydrolases (Da 
Silva et al., 2004; Fernandes-Pedrosa et al., 2008; Gremski et al., 2010). 
To sum up, the venom is a mixture of several hundred biologically 
active compounds that act synergistically, and the detailed mechanism 
of action remains unknown. The only consensus up to date is that 
Phospholipase D isoforms present in the venom are responsible for the 
pathology of envenomation in mammals. 
1.2. Phospholipase protein family 
The terminology employed for referring to the most relevant group of 
toxins in Loxosceles venoms has changed over time and deserves some 
attention. In 1976, toxins of around 34 kDa that affected rabbits and 
mice were isolated from Loxosceles reclusa venom (Geren et al., 1976). 
Later, in 1981, a fraction of around 31–37 kDa was isolated from the 
same venom which was able to kill mice, causes lysis of human eryth-
rocytes, affects human plasma coagulation, and produces dermonecrotic 
activity in rabbits (Babcock et al., 1981). By fractionation of venom 
content based on gel filtration and SDS-PAGE, it was found that the most 
abundant and also relevant toxin in this venom of Loxosceles gaucho had 
a molecular weight of about 35 kDa (Barbaro et al., 1992; Geren et al., 
1976). This fraction alone was able to produce necrotic lesions, in-
flammatory response, and platelet aggregation when inoculated to 
experimental animals, and thus it was named dermonecrotic toxin. In 
1998 Tambourgi et al. purified a 35 kDa fraction from Loxosceles inter-
media venom, which was resolved by reversed-phase chromatography 
into three peaks named P1, P2, and P3 (Tambourgi et al., 1998). 
Functional characterization allowed the authors to conclude that P1 and 
P2 were not only capable of inducing all the in vivo effects already 
described but also displayed Sphingomyelinase-D (SMase-D) enzymatic 
activity. Sphingomyelin (SM) or N-acyl-sphingosine-1-phosphorylcho-
line is a type of sphingolipid present in the plasma membranes of animal 
cells. Particularly in humans, SM comprises nearly 85% of all the 
sphingolipids in the outer leaflet of mammalian plasma membranes, 
having important functions as a structural membrane component. 
SMase-D (EC number 3.1.4.41) catalyzes the hydrolysis of SM, resulting 
in the formation of ceramide1-phosphate (CIP) and choline (Meeteren 
et al., 2004; Tambourgi et al., 2010). Then, many authors referred to 
these toxins both as SMase-D or dermonecrotic toxins. Between 2002 
and 2004, the amino acid sequences of SMase-D from several Loxosceles 
species were reported and cloned, and recombinant versions of these 
proteins were obtained, thus allowing further insight into their func-
tional properties (Fernandes Pedrosa et al., 2002; Kalapothakis et al., 
2002; Ramos-Cerrillo et al., 2004). It was then observed that these 
proteins were able to hydrolyze not only SM but also other phospho-
lipids such as lysophosphatidylcholine (LPC) (Lee and Lynch, 2005). 
LPC hydrolysis in the presence of Mg2þ-cofactor releases lysophospha-
tidic acid (LPA), triggering LPA signaling pathways. Further on, they 
appeared to act in vivo on a broad range of bioactive lipids to exert their 
toxicity (Chaim et al., 2011). To account for a more generalized 
description of their enzymatic activity, the alternative Phospholipases D 
(PLD) name was proposed for referring to these toxins. Moreover, some 
authors have recently proposed that the enzymatic activity of these 
proteins in vivo should not be hydrolysis of their phospholipidic sub-
strates but transphosphatidylation, forming cyclic phosphate products 
which exert their biologic effects (Lajoie et al., 2013). Based on cDNA 
sequence similarity to material extracted from venom glands, Kalapo-
thakis et al. suggested a new and somehow more integrative nomen-
clature for these toxins: LoxTox (Kalapothakis et al., 2007). Therefore, 
many proteins with a high degree of homology, sharing important 
structural and functional motifs, could be grouped together without the 
need to analyze their enzymatic or biological activity. These changes in 
terminology significantly increased the number of molecules recognized 
as members of this group: from the initial one to three isoforms identi-
fied per species based on biological or enzymatic criteria, proteomic and 
RNA sequence homology studies were able to incorporate up to 23 
isoforms from a single spider species to this protein family group (Dantas 
et al., 2016; Fernandes Pedrosa et al., 2002; Kalapothakis et al., 2007, 
2002; Ramos-Cerrillo et al., 2004). Moreover, based on sequence simi-
larity, Binford et al. proposed that new integrative gen grouping could 
be extended to all the members of the Siicaridae family, creating the 
SicTox gene family (Binford et al., 2009). Although both gene grouping 
proposals seem plausible, considering a historical perspective and for 
the sake of simplifying the comparison among the different studies 
reviewed in this manuscript, we will keep the traditional PLD naming for 
these proteins. 
1.3. Immunotherapeutics treatment for envenomation 
Loxosceles antivenom showed clinical effectiveness when properly 
applied and its use is recommended by several ministries of health 
(Instituto Nacional de Salud, 2004; Minist�erio da Saúde, 2001; Minis-
terio de Salud, 2012; Pauli et al., 2009, 2006). However, its real use-
fulness is controversial (Hogan et al., 2004; Isbister et al., 2003; Isbister 
and Fan, 2011; Isbister and White, 2004; Swanson and Vetter, 2005; 
White et al., 2003). This controversy is logical and due to various rea-
sons: available studies on human beings are conflicting and mostly no 
placebo-controlled, the criteria to apply the antivenoms is not unani-
mous (doses, routes, time of application after the bite), the specie of 
spider and the site of bite, the characteristic of patients and the criteria 
to evaluate the results of the treatment, which are not unanimous 
(Isbister and Fan, 2011; Pauli et al., 2006). Nevertheless, the most 
important point is the lack of clinical trials designed ad hoc (Isbister and 
Fan, 2011). Experimental studies despite very different results and 
methodologies show that the antivenoms are able to limit cutaneous 
lesions caused by the venom and to rescue mice from lethal 
challenge-doses (de Roodt et al., 2007; Gomez et al., 1999; Pauli et al., 
2009, 2006). However, experiments must not be directly extrapolated to 
the clinical usefulness of this or another antivenom (Isbister and Fan, 
M. Fingermann et al.                                                                                                                                                                                                                           
Toxicon: X 6 (2020) 100036
4
2011; Theakston and Reid, 1983; World Health Organization, 2017, 
1981). 
Since 1954, when it was developed in Brazil and after the beginning 
of their industrial production in 1961 (Furlanetto, 1961; Isbister and 
Fan, 2011), this antivenom is broadly used and at present is produced by 
sanitary official institutions from South American countries (Argentina, 
Brazil and Peru) and by a private Laboratory in Mexico (Cabrerizo et al., 
2009; Fan et al., 2019; Temprano et al., 2017). In these South American 
countries the spider bites are of mandatory notification to national au-
thorities and represent around 1,200 to 23,000/year, being those caused 
by Loxosceles from 400 to over 7,000 cases/year, while the lethality vary 
from 0.001–1.5% (de Roodt et al., 2007, 2002b; Ministerio da Saúde, 
2020; Minist�erio da Saúde, 2001; Ministerio de Salud, 2012; Vargas, 
2017). Data from Brazil in the last years indicates around 7,000 
cases/year of accidents by Loxosceles (Ministerio da Saúde, 2020; Min-
ist�erio da Saúde, 2001) and the antivenom use vary, considering avail-
able data, from 11.9% to 70% of the cases, with a median of 51% 
(Ministerio de Saúde 2001). The lethality ranges from 0.1% to 1.5%, 
depending on the region and the species of Loxosceles, being the most 
severe cases those due to Loxosceles laeta, the species of higher sanitary 
importance in Peru, Chile, Brazil and Argentina (Gonçalves-de-Andrade 
and Tambourgi, 2003; Minist�erio da Saúde, 2001; Pauli et al., 2006). In 
Argentina, with over 1,200 spider bites/year and 0.15% of lethality (de 
Roodt et al., 2017; Ministerio de Salud, 2013), considering that Lox-
osceles would be responsible of around 30% of spiders bites (de Roodt 
et al., 2002b), 300–400 Loxosceles accidents/year could be estimated, 
with a use of antivenom over 50% (de Roodt, unpublished data). In Peru, 
with around 1,400 Loxosceles bites/year, the national lethality by in the 
period 2011–2017 was around 0.001–0.5% (Vargas, 2017) but unfor-
tunately we could not obtain information regarding the use of anti-
venom. In Mexico the accidents are not of mandatory report and 
possibly 100 cases/year occurs (Secretaría de Salud de M�exico, 2017) 
with no official data or epidemiological reports available regarding 
antivenom use or deaths. 
Data regarding Loxosceles bites or treatments in other countries are 
fragmentary or absent, since these accidents are not reported or are only 
partially reported to sanitary authorities. In Chile, where the exact 
number of cases in the country is not known and where the anvinenom is 
not used (Ministerio de Salud, 2016) the mortality reported was around 
3% (Harz-Fresno et al., 2015; Ministerio de Salud, 2016; Schenone et al., 
1989) with a 20–25% of lethality in the systemic envenomation (del 
Puerto et al., 2018). In Chile like in Argentina and Peru, Loxosceles laeta 
would be the most important species of Loxosceles involved with 
accidents. 
Despite the scarcity of available information from clinical studies, 
there is a consensus in the countries where the antivenom is used that an 
early start of antivenom treatment helps to prevent dermonecrotic le-
sions from extending and limits systemic compromise (Minist�erio da 
Saúde, 2001; Ministerio de Salud, 2012; Pauli et al., 2006; Tambourgi 
et al., 2010). The active pharmaceutical ingredients of antivenom are 
immunoglobulins (Peruvian antivenom) or their F (ab’)2 fragments 
purified from plasma of animals (equines) hyperimmunized with 
different Loxosceles venoms or with recombinant PLDs (Mexico). The 
high homology present in their venoms and PLDs is responsible of an 
important immunological cross reactivity that turn the available thera-
peutic antivenoms able to be used in non-specific envenoming since this 
cross reactivity is able to provide enough cross-protection levels to pass 
in vivo tests employed for antivenom quality assessment (Barbaro et al., 
2005; de Roodt et al., 2007) and their use as therapeutic tools, as these 
are used since several years ago in different South American countries. 
The lower mortality reported in countries where the antivenom is 
used empirically suggests its usefulness, at least to treat systemic enve-
noming, when is properly applied (Instituto Nacional de Salud, 2004; 
Minist�erio da Saúde, 2001; Ministerio de Salud, 2012). Nevertheless, 
other factors should be in addition considered before to affirm this, and 
more information is necessary to clarify these differences. By this reason, 
well-designed clinical trials would clarify these points and would help to 
adjust the protocols for the different types of envenoming, turning the 
empiric knowledge in scientific knowledge. 
Venom availability poses a severe restriction for antivenom pro-
duction. While about 50 μg of proteins are extracted in every 0.15–0.45 
μl drop of venom after electrostimulating each spider, mg quantities are 
required per horse in every hyperimmunization schedule (de Roodt 
et al., 2002a; Morgan, 1969; Ospedal et al., 2002). For this reason, ef-
forts were undertaken to achieve reduced immunization schemes such 
as in anti-L. laeta venom production (de Roodt et al., 2002a). As already 
discussed, PLD proteins are responsible for venom toxicity. Between 
2002 and 2004, the first complete amino acid sequences from members 
of this family were reported for several Loxosceles species (Fernandes 
Pedrosa et al., 2002; Kalapothakis et al., 2002; Ramos-Cerrillo et al., 
2004). Soon afterward, several groups directed their efforts toward the 
recombinant expression of these proteins focused on reducing the 
amount of Loxosceles venom needed for antivenom production. A PLD 
from L. laeta (clone H17) was the first toxin of this class to be cloned and 
expressed in recombinant form in Escherichia coli (Fernandes Pedrosa 
et al., 2002). This recombinant PLD, with a molecular weight of 33 kDa, 
showed dermonecrotic and complement-dependent hemolytic activities. 
Noteworthy, antiserum raised against this recombinant protein was able 
not only to recognize a 32-kDa protein in crude L. laeta venom but also to 
block the dermonecrotic reaction caused by whole L. laeta venom. Thus, 
this study conclusively confirmed the principal role of PLD proteins in 
the pathology of Loxosceles spider envenomation. The number of reports 
on the recombinant PLD expression from different Loxosceles species 
soon started to grow (Table 1). Between 2002 and 2004, the first reports 
appeared for L. intermedia, in 2005 for L. reclusa, in 2006 for L. boneti, 
and finally in 2013 for L. gaucho (Araujo et al., 2003; Kalapothakis et al., 
2002; Lee and Lynch, 2005; Magalh~aes et al., 2013; Olvera et al., 2006; 
Tambourgi et al., 2004). Brown spiders express several highly homolo-
gous isoforms of PLD with an identity varying from 40 to 90% (de Roodt 
et al., 2007; Tambourgi et al., 2010). According to sequence identity, 
biochemical activity, and molecular modeling, these proteins are 
grouped into two classes: Class I enzymes possess a single disulfide 
bridge and contain a variable loop whereas members of Class II enzymes 
contain an additional intra-chain disulfide bridge that links a flexible 
loop with a catalytic loop (Murakami et al., 2006). Both classes exhibit 
differences in their toxic potential, and Class II enzymes are less toxic 
than Class I enzymes (de Santi Ferrara et al., 2009). At first glance, the 
fact that over 20 PLD isoforms can be identified in a single venom gland 
could be discouraging when the objective of obtaining an antivenom 
from recombinant expression of a single clone is set. Nevertheless, re-
combinant PLD successfully replaced whole venom for equine hyper-
immunization during antiserum production (De Almeida et al., 2008; 
Duarte et al., 2015; Olvera et al., 2006), and the antivenom produced 
using these recombinant enzymes as immunogen showed clinical effi-
cacy and is currently in use in Mexico (G�omez-Rivera et al., 2014; 
Grashof et al., 2020; S�anchez Villegas et al., 2014a, 2014b; S�anchez 
Villegas and Rodríguez �Alvarez, 2015). Antivenom produced from re-
combinant PLD conferred full protection against dermonecrotic effects 
of venom from the same Loxosceles species and at least partial 
cross-protection from venoms of different species. Unfortunately, the 
toxicity of recombinant PLD to horses is still present, thus limiting the 
amount of immunogen and the frequency of hyperimmunization plans. 
To avoid PLD’s toxicity and with the initial aim on obtaining a potential 
vaccine candidate, several groups directed their efforts toward the 
construction of recombinant chimeric proteins expressing only selected 
B cell epitopes from PLD (Calabria et al., 2019; de Almeida Lima et al., 
2018; Felicori et al., 2009; Figueiredo et al., 2014; Souza et al., 2018). In 
these chimeric proteins, as opposed to full recombinant PLD proteins, 
the lack of enzymatic activity results in an absence of toxicity. Their 
potential use for reducing the use of venom for antivenom production 
was also evaluated, as mentioned in Table 1 (Calabria et al., 2019; de 
Almeida Lima et al., 2018; Figueiredo et al., 2014; Souza et al., 2018). 
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When the results obtained between chimeric proteins displaying 
selected PLD epitopes against full-length PLD recombinant proteins are 
compared, two immediate conclusions can be extracted. Full replace-
ment of venom in equine immunization schedules only leads to com-
parable results to full venom immunization schedules when full-length 
PLD isoforms and not when chimeric proteins are used (De Almeida 
et al., 2008; Figueiredo et al., 2014; Olvera et al., 2006). Nevertheless, 
chimeric proteins are able to reduce the need for whole venom by up to 
67% (Figueiredo et al., 2014). Chimeric proteins might bring an op-
portunity to simultaneously raise an immune response to epitopes from 
PLD isoforms of different Loxosceles species together with those from 
other venom components. Thus, chimeric proteins displaying epitopes 
from the Loxosceles metalloproteases LALP-1 and LgALP-1, the hyal-
uronidase LiHYAL together with conformational and/or linear epitopes 
from the PLD isoforms of one or more Loxosceles species were con-
structed and used to immunize different animals of experimentation 
(Calabria et al., 2019; de Almeida Lima et al., 2018; Souza et al., 2018). 
The sera from the immunized animals proved to be effective for the 
neutralization of selected catalytic activities (sphyngomielinase, fibri-
nogenase and hyaluronidase activities) in the venom. Nevertheless, the 
formulations based on these chimeric proteins prove to be poorly 
immunogenic: about ten times as much the mass of chimeric proteins as 
compared to venom was required in immunization schedules to achieve 
at least partial protection from the pathological effects of venom inoc-
ulation in animal models (Calabria et al., 2019; Souza et al., 2018). 
Thus, at current state-of-the-art, recombinant PLD isoforms are the main 
immunogen in second-generation antivenoms production, which could 
allow partial or potentially complete venom replacement. 
2. Discussion 
Within the venom-dependent approaches, it is very important to 
investigate novel delivery systems, adjuvants, and detoxification stra-
tegies of the whole venom or individual toxins to enhance immune re-
sponses and antibody neutralization capacity. 
As already discussed, PLD isoforms are the only recombinant anti-
gens from Loxosceles venom, at least to our knowledge, that have been 
used for venom replacement during antivenom production.. So far, the 
recombinant expression of PLD isoforms has been performed exclusively 
in traditional prokaryote systems. The incorporation of these method-
ologies to antivenom production requires bioreactors, bacterial ho-
mogenizers, dedicated facilities, and specifically trained personnel. 
E. coli is still the workhorse of gene expression, but unfortunately, many 
recombinant toxins expressed as inclusion bodies require exhaustive in 
vitro refolding steps to recover their biological activities. Although many 
authors report the successful expression of soluble recombinant PLD 
isoforms, others found it to be a hard task, observing that the insoluble 
fractions of PLD are poorly immunogenic (Catal�an et al., 2011; Felicori 
et al., 2006; Fernandes Pedrosa et al., 2002; Kalapothakis et al., 2002; 
Magalh~aes et al., 2013; Olvera et al., 2006). Eukaryotic systems are 
usually less prone to express heterologous eukaryotic proteins as insol-
uble fractions. Nevertheless, expression in eukaryotic cell lines is 
significantly more expensive than expression in prokaryotes. But other 
promising biotechnological platforms, like lepidopteran larvae, deserve 
attention. Insect larvae are reared and inoculated with recombinant 
baculoviruses in insectaria under conditions similar to those required for 
the venomous arthropods used in venom production. Micro to milligram 
expression of different recombinant proteins per larvae have been re-
ported with this system (Targovnik et al., 2016). Once the proteins are 
expressed, they are easily recovered from larval extracts by simply use of 
blenders and filtrating the homogenate. Downstream processing from 
this step-on is similar for both prokaryotic and larvae expression sys-
tems. We have indeed successfully expressed microgram amounts per 
larvae of an isoform of PLD in both S. frugiperda and Rachiplusia nu with 
conserved dermonecrotic activity (unpublished results). Estimating the 
costs for producing PLD isoforms in prokaryotic and larvae expression 
systems is suggestive. For this estimation we considered the following 
assumptions: we centered our calculations in the potential demand of 
Brazil, the country with the highest reported incidence of loxoscelism. 
The amount of antigen needed was estimated from the available infor-
mation from various immunization schedules reported in the literature. 
A 40% yield can be considered acceptable for F (ab’)2 based antivenom 
production. Taking also into account the number of vials that are indi-
cated for treatment by the National Health authorities of that country 
and a 5% severe outcome after Loxosceles envenomation, about 440 mg 
of recombinant PLD isoforms would be needed to satisfy the needs of an 
yearly production of antivenoms to treat all loxoscelesic accidents in 
that country. Average reported yield for prokaryotic expression systems 
is near 10 mg/L, then 44 L of cultured bacteria would satisfy the yearly 
demands from this country. This could be achieved in laboratory to pilot 
scale industrial microbiology facilities. In our hands, about 27,000 
larvae would be required to match this yearly recombinant protein 
needs. Oral infection with occlusion bodies (OB) through their diet is 
perfectly suited to perform this task. Thus, upstream processing in this 
simple platform offers an easy-to-implement alternative for regular in-
sect producing facilities at significantly lower costs when compared to 
laboratory or pilot scale industrial microbiology facilities. 
Another relevant aspect of recombinant PLD expression deserves 
further attention. Horses, like humans, are particularly susceptible to the 
toxic effects of PLD (Olvera et al., 2006). This is a relevant aspect to be 
considered for antivenom production. The chemical or genetic modifi-
cation of specific histidine and/or glutamic residues on PLD sequence 
completely abolishes their enzymatic activity, and thus their toxic po-
tential (de Andrade et al., 2006; Vuitika et al., 2016). Noteworthy, cir-
cular dichroism studies show that this loss of activity occurs without 
altering PLD’s native (α/β)8 TIM-like barrel structure and as such, 
immunogenic potential. This opens the door to the recombinant 
expression of genetically inactivated PLD isoforms for the production of 
antivenoms, which would have several advantages: minimizing animal 
suffering, increasing productivity, shortening the time of antibody pro-
duction (as compared with the present methods of immunization, 
especially in naïve horses), and minimizing animal tissue damage. The 
recombinant expression of these atoxic PLD variants has so far been 
focused on characterization and structure elucidation studies but not at 
the scale of the immunogen production process. The sole available 
reference, at least to our knowledge about the use of site-directed 
genetically detoxified PLD for antivenom production is reported in a 
patent, with successful results according to the authors (Olvera Rodri-
guez et al., 2012). 
3. Conclusion 
Loxosceles antivenom production may have several drawbacks, 
particularly the complexity of the procedure to obtain venom and its low 
yield. In fact, a high amount of spider venom is needed for immunizing 
horses during antivenom production and for antivenom control. Using 
recombinant immunogen, the amount of required venom for the control 
steps would drastically drop, highly improving production efficiency. 
Therefore, more studies focusing on the recombinant production of 
some toxins like PLD are imperative. New recombinant immunogens 
produced at mg to gram levels by simple low-cost technologies, with 
high immunogenicity and low toxicity, are expected to change anti-
loxosceles venom production in the not-too-distant future. 
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